During the 2012 DIA Annual Meeting, while folks flooded to the ERT booth to grab a cup of coffee, we asked those waiting in the queue to fill out a brief questionnaire regarding their perceptions of the Clinical Outcome Assessments/ePRO industry and likely trends they expect to see in the future. Below are your results from the nearly 200 people who responded to the ePRO Community survey. Thanks again to all of those who stopped by the booth to learn more about ERT’s products and services!
About 30% of clinical studies currently collect some sort of Clinical Outcome Assessment. Do you think you will be collecting more PRO data in future trials?
Over 80% of respondents expect to see more PRO data in their future clinical trials.
Which of the following vendors do you associate with collecting ePRO/eDiary data?
How important is it for the vendor to have a scientific expert on staff to help consult and guide you in the way that the ePRO solution is commissioned?
A total of 77% of respondents indicated it was either important or very important to have a scientific expert on staff.
In terms of technology used by the patient (PDA, IVR, Web, Digital Pen), how important is the device in your decision-making process?
A total of 70% of respondents indicated device selection was either important or very important in their decision-making process.
What other factors are important to you when making a decision on what ePRO vendor to choose?
The top five other factors that are important when choosing an ePRO vendor include: Proven Track Record, Therapy Area Experience, Price, Integration with other Clinical Technologies (e.g. EDC), and Prior Experience of Collecting Data Using a Specific Gold Standard Instrument / Assessment.
In 5 years’ time what do you think will be the most widely used methods of collecting PRO data?
Not to anyone’s surprise, the combination of Tablet, Smartphone and Web responses accounted for over 75% of replies, while paper had a rating of merely 3%. Collecting data on a Tablet or iPad had the highest percentage rating at 31%.